Skip to main content
Hilary Stobart on Muck Rack

Hilary Stobart

As seen in: Nature, The BMJ, EJSO - European Journal of Surgical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Hilary

Contact Hilary, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring

|
By S. R. Doyle, J. Brunekreef, E. A. Marcus, Y. Liu, E. Sawyer, A. M. Thompson, S. E. Pinder, Jelle Wesseling, Alastair Thompson, Serena Nik-Zainal, Elinor Sawyer, Helen Davies, Andrew Futreal, Nicholas E Navin, E. Shelley Hwang, Jos Jonkers, Jacco van Rheenen, Fariba Behbod, Esther H. Lips, Marjanka K. Schmidt, Lodewyk Wessels, Daniel Rea, Proteeti Bhattacharjee, Hilary Stobart, Deborah E. Collyar, Donna Pinto, Ellen Verschuur, Marja van Oirsouw, J. Wesseling, E. H. Lips, M. A. Oerlemans, L. Mulder, I. Bouybayoune, C. I. Sánchez, J. Teuwen
| Nature Verified
Abstract Ductal Carcinoma In Situ (DCIS) is a non-obligate precursor of invasive breast cancer. Due to a lack of reliable prognostic markers, nearly all women with DCIS undergo intensive treatment—often unnecessarily. The LORD trial addresses this by offering active surveillance to women with screen-detected, ER-positive, HER2-negative, grade 1 or 2 DCIS, aiming to reduce overtreatment.
Open in Who Shared Issue with article?

Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients

|
By Philipp Heumann, Miguel E. Aguado-Barrera, David Azria, Erik Briers, Jenny Chang-Claude, Ananya Choudhury, Alison Dunning, Laura Fachal, Antonio Gomez-Caamano, Sara Gutiérrez-Enríquez, Rudolf Kaaks, Sarah L. Kerns, Barry Rosenstein, Dirk De Ruysscher, Martina Schmidt, Elena Sperk, Hilary Stobart, Marlon R. Veldwijk, Tim Ward, Adam Scott Webb, Catharine West, Tiziana Rancati, Tim Rattay, Christopher Talbot, Petra Seibold, Harkeran K. Jandu, Olivia Fuentes-Ríos, Maarten Lambrecht, R. Paul Symonds, Liv Veldeman
| Nature Verified
Abstract Fatigue is a common symptom of cancer patients, which can impair quality of life even years after treatment. Little is known about genetic determinants of fatigue, especially in prostate cancer (PCa). This study aims to identify SNPs associated with long-term fatigue in a prospective cohort of PCa patients. A genome-wide association study was conducted in non-metastatic PCa patients treated with radiotherapy in 7 European countries and the USA.
Open in Who Shared Issue with article?

Patients need information on the risk of second cancer after early breast cancer

|
By Mairead MacKenzie, Hilary Stobart, David Dodwell, Carolyn Taylor
| The BMJ Verified
Mairead MacKenzie, patient author1*, Hilary Stobart, patient author1*, David Dodwell, oncologist2, Carolyn Taylor, professor of oncology2 1Independent Cancer Patients’ Voice (ICPV), London, UK 2Nuffield Department of Population Health, University of Oxford, Oxford, UK *Authors contributed equally Correspondence to: D Dodwell david.dodwell{at}ndph.ox.ac.uk Patients with early breast cancer often have concerns about their risk of a second cancer following treatment.
Open in Who Shared Issue with article?
See all 8 licensed articles (10 Total)